Aegerion Pharmaceuticals Inc.

Aegerion Pharmaceuticals Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile.
Biotech Week; 12/2/2009; 1550 words; Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused...Sasiela, Chief Medical Officer of Aegerion Pharmaceuticals, said, "The promising...About Aegerion Pharmaceuticals, Inc. Aegerion Pharmaceuticals, Inc...

Medicines Co.'s Cangrelor Shows Promise Following Earlier Miss.
BIOWORLD Today; 11/18/2009; 1444 words; ...AHA news: o Aastrom Biosciences Inc., of Ann Arbor, Mich., reported...treatment on atherosclerosis. o Aegerion Pharmaceuticals Inc., of Bridgewater, N.J...percent at 56 weeks. o Aldagen Inc., of Durham, N.C., said...

Aegerion's Series A Adds $22M For Cholesterol-Lowering Work.
BIOWORLD Today; 11/3/2009; 1209 words; ...was founded in February 2005, Aegerion Pharmaceuticals Inc. raised $22.5 million in...combination market." That's where Aegerion's AEGR 733, a microsomal triglyceride...based Merck & Co. Inc. called Zocor (simvastatin...

Aegerion Pharmaceuticals Announces Final Lomitapide (AEGR-733) Phase II Data.
Clinical Trials Week; 7/6/2009; 1326 words; Aegerion Pharmaceuticals, Inc., a biopharmaceutical...preliminary results Aegerion announced in November...About Aegerion Pharmaceuticals, Inc. Aegerion...Company Contact: Aegerion Pharmaceuticals, Inc. Will Lewis, Co...

Aegerion Pharmaceuticals Announces Final Lomitapide AEGR-733 Phase II Data.
Clinical Trials Week; 6/29/2009; 617 words; ...Pharmaceuticals, Inc., a biopharmaceutical...see also Aegerion Pharmaceuticals, Inc.). The...Clinical Trials, Pharmaceutical, Biopharmaceuticals...Disease, Pharmaceuticals, Protein...Therapies, Aegerion Pharmaceuticals Inc. This article...